Navigation Links
Hospira Reports Third-Quarter 2009 Results
Date:10/27/2009

$533.8 $362.4 $2.23 ========= ========== ====== ======= GAAP results for the nine months ended September 30, 2009 include: A -- Project Fuel charges: $12.6 million reported in Cost of products sold, $67.9 million reported in Restructuring and impairment, $2.6 million reported in Research and development and $22.4 million reported in Selling, general and administrative. These charges relate to the Project Fuel initiatives and include costs for severance and other employee benefits, process optimization implementation, other asset charges, exit costs and charges associated with certain non-strategic businesses and underlying assets committed for disposal and the related inventory, property and equipment, allocated goodwill and intangible assets. B -- Facilities Optimization charges: $8.9 million reported in Cost of products sold and $11.2 million reported in Restructuring and impairment. These charges relate to facilities optimization from the closure or departure from certain manufacturing and research and development ("R&D") facilities and include costs for severance and other employee benefits, accelerated depreciation and relocation of production and R&D operations. C -- Amortization of Mayne Pharma Limited ("Mayne Pharma") intangible assets resulting from the Mayne Pharma acquisition is reported in Cost of products sold. D -- Impairment of marketable equity securities is reported in Other expense (income), net. E -- Resolution of IRS tax audit benefit of $91.9 million reported in Income tax expense (benefit). This discrete income tax benefit is related to the completion and effective settlement of Hospira's 2004 and 2005 U.S. tax return audits. Nine months ended S
'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received ... to initiate a Phase 1/2a clinical trial of its ... injury.  The approved trial follows the successful completion of ... is designed to assess safety and activity of escalating ... cord injuries, the first targeted indication for AST-OPC1 and ...
(Date:8/26/2014)... STATESVILLE, N.C., Aug. 26, 2014  Kewaunee Scientific Corporation ... its first quarter ended July 31, 2014. ... sales of $32,003,000 in the first quarter last year. ... per diluted share, as compared to net earnings of ... quarter of the prior year. However, both sales and ...
(Date:8/26/2014)... 26, 2014 Research and Markets ... Meter Industry Report 2014 " report to their ... Report 2014 is a professional and in-depth study on ... The report provides a basic overview of ... structure. The glucose meter market analysis is provided for ...
Breaking Medicine Technology:Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6Global Glucose Meter Industry Report 2014 2Global Glucose Meter Industry Report 2014 3
(Date:8/27/2014)... Casey Diekman, assistant professor of mathematical sciences ... to gain greater insight into the biological clock that ... harmonized the behavior of humans and all other mammals ... of light and dark experienced each day and with ... related to natural patterns of sleep/wake behavior which, when ...
(Date:8/27/2014)... Time to Play Golf, a fast-growing ... , With 80-degree temperatures and only partially clouded skies, ... (TTPGolf) Inaugural Outing. Around 50 golfers showed up to duel ... beautiful Heron Glen Golf Course in Ringoes, New Jersey. , ... to be having a great time. Birdies were dropping and ...
(Date:8/27/2014)... August 27, 2014 President Obama is ... immigration. A White House initiative that supplies green ... undocumented immigrants would also open a pathway to Social ... , Access to work authorization would add new ... the program is the target of proposals to cut ...
(Date:8/27/2014)... The use of ESAs to treat ... may eliminate the need for blood transfusion and associated ... webinar, Dr. Zanhua Yi, board certified in hematology, oncology, ... necessity of erythropoiesis-stimulating agents (ESAs) in the treatment of ... Food and Drug Administration (FDA) has approved three ESAs ...
(Date:8/27/2014)... Michael A. Bottar has been ... Best Lawyers In America© for the practice areas of ... - Plaintiffs." , Bottar received his undergraduate degree from ... of Syracuse University College of Law where is an ... of the Syracuse Law Review Survey of New York ...
Breaking Medicine News(10 mins):Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 2Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 3Health News:NJIT Researcher Receives New NSF Funding to Study Fundamental Rhythms of Life 4Health News:Recap: Time To Play Golf Inaugural Golf Outing 2Health News:The Senior Citizens League (TSCL) Warns: White House Action On Immigration Could Give Social Security To Known Illegals 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 3Health News:Michael A. Bottar Selected For Inclusion In The Best Lawyers In America© 2015 2
... 25 - "We are excited about,the strong efforts in ... facility," said Judie Brown, president of American Life,League., ... nation,with 287 surgical and medical abortion facilities across the ... abortion operation in the,Denver suburb of Stapleton and local ...
... stem cells that differentiate into bone appears to cause regeneration ... strategy for osteoporosis, according to a report in the February ... by researchers from Massachusetts General Hospital (MGH) and the Harvard ... medication used to treat bone marrow cancer improved bone density ...
... while eating out in the New Year, SAN ... the New Year,s resolution list. But for the thousands ... is not always,easy. Today, American Express issued its Tastemaker ... best San Francisco restaurants where diners,can get a fresh, ...
... 25 3.5 million lives could be,saved over the ... and treatment measures in the 30 hardest hit countries ... the World Economic,Forum. Additionally, rapid scale-up would increase annual ... prevent 672 million malaria cases, and,free up 427,000 needed ...
... of teenagers may have metabolic syndrome, a clustering of risk ... and diabetes in adulthood. This shocking statistic represents some of ... in children and adolescents a necessary starting point for ... in youth than it has been in adults. , With ...
... Full Year 2007 Revenue of Approximately $154 million, Announces Full ... ... SAN DIEGO, Jan. 25 NuVasive, Inc. (Nasdaq:,NUVA), a medical ... for the spine, today announced,preliminary unaudited financial results for the ...
Cached Medicine News:Health News:Turning on adult stem cells may help repair bone 2Health News:Eating Healthy in the New Year? American Express Tastemakers Dish on the Top San Francisco Restaurants for Grabbing a Healthy Bite 2Health News:Eating Healthy in the New Year? American Express Tastemakers Dish on the Top San Francisco Restaurants for Grabbing a Healthy Bite 3Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 2Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 3Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 4Health News:Metabolic syndrome affects nearly 1 in 10 US teens 2Health News:Metabolic syndrome affects nearly 1 in 10 US teens 3Health News:NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 2Health News:NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results 3
Frequency 55 Toric XR is a great option for those with high levels of astigmatism...
... SofLens66 Toric lens are fit ... current soft toric lens wearers who ... with the health and convenience of ... want the convenience of contact lenses; ...
The Heine C series binocular loupes offer extremely low weight (46g), crisp views, and quality German construction in an affordable instrument....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
Medicine Products: